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Summary
INTRODUCTION
 Globally, cervical cancer is the second most regular malignant growth in females after 
breast cancer. Timely recognition of premalignant lesions is an essential segment in the decrease 
of related morbidity and mortality. Though Pap -Smear test has been a helpful screening device 
despite hampered by high intra and interobserver changeability, false negatives at 20– 30% and 
false positives at 5– 70%.  
OBJECTIVE
 
 The study was to determine the role of p16INK4a biomarker in the identification of low 
grade Squamous Intraepithelial lesions in cellblocks prepared from Pap smears and subsequently 
compared with previous Pap smear results with Colposcopy and Cellblock results.
METHODOLOGY
 This was a laboratory-based, prospective study with a parallel comparative arm at 
Kenyatta National Hospital Reproductive health clinic (66). All patients who had abnormal Pap 
smear reports and referred for Colposcopy, and consented for the study were enrolled. A smear 
was taken just before taking a Colposcopy biopsy. The cytobrush was immediately put in Acid 
alcohol fixative centrifuged and deposits wrapped in a filter paper and processed histologically 
to form a cellblock. Colposcopy biopsies were then retrieved from KNH histology Lab and both 
samples subjected to Routine histological stain and eventually with biomarker p16. Total of 85 
samples was collected. 
 RESULTS
 There was a significant level of agreement between Pap smears and cellblock findings 
on the routine Histological stain. Of the 58 cases analyzed Colposcopy had (39%) 27 negatives 
and (45%) 31 positives while cellblock had (48%) 33 negative and (36%) 25 positive for pre and 
malignancy with a confidence interval of 0.016 as the margin of error. Biomarker Colposcopy 
had (43%) 30 negativity and (41%) 28 positivity while cellblock had negativity of (46%) 32 and 
positivity of (38 %) 26 
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CONCLUSION
 Poor inter-rater agreement resulting to mortality and  morbidity associated with false 
positives and false negatives,  cellblock prepared from residues of cytobrush stained with 
Haematoxyline and Eosin and biomarker is likely to circumvent all the above,  together with 
minimizing loss to follow up as patients only visit health facility once and they acquire all the 
results without resampling hence drastically reducing the cost of colposcopy, which require highly 
specialized equipment and experienced personnel who are very few and difficult to find.
 [Afr. J. Health Sci. 2019; 32(2): 39 - 48 ]
Introduction
 Worldwide, cervical malignancy is the second 
most regular disease in ladies after breast cancer. 
Opportune location of premalignant sores is a critical 
part to decrease the related morbidity and mortality [2]. 
 Pap test has been a helpful “screening tool 
however hampered by high inter and intra-observer 
fluctuation”. This has brought about high false negative 
and false positive rates that extend between 20– 30% 
and 5– 70% respectively [3, 4]. 
 Specificity and sensitivity in Pap smear for 
HSIL using LBC have not been shown to improve 
though. Colposcopic cervical biopsies are “considered 
as the gold standard, though hampered by intra- and 
inter-observer variability” [5, 6].
 HPV testing is productively incorporated 
into the essential screening, either as an assistant to 
cytology or as a sole essential test. In any case, it fails 
in the triage of low-grade lesions, and regardless of 
whether actualized as an essential screening test, it is 
“important to have a more disease explicit triage marker 
to distinguish women that would need to undergo 
colposcopy”[7]. 
 Moreover, a solitary HPV DNA test can affirm 
infection by the virus, present in 99.7% of every cervical 
malignancy; it doesn't segregate among transient and 
unending disease [8]. 
 Performing IHC on cervical smears could evade 
this impediment [9], circumvent invasive interventions 
and avert possibly increased morbidities by using target 
choices at the negligibly intrusive cervical cytology 
stage. 
 The epidemiology of cervical cancer, just as 
experimental examinations, demonstrates that the 
development of cervical cancer predetermined by 
various etiological factors but the infection with the 
human papillomavirus (HPV) is the utmost factor 
towards the development of the disease [10]
 HPV DNA is available in about 95% of 
Squamous Cell Carcinomas while in Adenocarcinoma 
of the cervix, has been recognized in just about 70% 
to 90% [10].    Because of population-based Pap smear 
screening, the frequency of Squamous Cell Carcinoma 
has reduced remarkably in most developed and some 
developing nations, while amid a similar period, there has 
been a relative increment in the rate of adenocarcinoma 
among women. A few investigations have detailed this 
escalation, particularly in young women [7]. 
 The development of adenocarcinomas cannot 
be effectively prevented by cytological screening 
alone. The various grades of dysplasia can be used to 
distinguish the precancerous phases of invasive cervical 
carcinoma and characterize the stages of development. 
It is proposed that around “12% of all carcinomas in-
situ, when left untreated, advanced into obtrusive 
malignancy after 13 years” [11, 12]. 
 The “history of cervical intraepithelial neoplasia 
(CIN) is extremely variable” and unpredictable when 
left untreated, CIN may revert to normal, either persist 
or eventually advance to intrusive cervical malignant 
growth. The investigation of those that will progress or 
relapse has critical clinical value[13]
 p16INK4a, a tumor silencer gene, is a component 
of the p16INK4a/cyclinD - CDK4/6/Rb pathway[14]. 
It can initiate G1 cell cycle capture by repressing the 
phosphorylation of pRb by CDK4 and CDK6[12]
 Recent investigations have demonstrated 
that immunohistochemical staining techniques with 
p16INK4a is a promising marker for dysplastic and 
cancerous cervical epithelia [15]. 
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 Different examinations have likewise shown 
that overexpression of p16INK4a aids the recognition 
of high-hazard HPV-related cervical squamous lesion 
[16]. 
 It was suggested that p16INK4a is valuable 
for recognizing immature Squamous Metaplasia 
which forms a high-grade Squamous Intraepithelial 
lesion, where the previous could act like a morphologic 
differential diagnosis [ 17].
 p16INK4a immunostain is used as a marker 
for identifying dysplastic lesions caused by HR HPV 
and in distinguishing non-HPV-related changes, such 
as squamous metaplasia, inflammatory conditions 
or reactive conditions that either mask or mimic 
dysplasia in the cervical biopsy specimen, from HPV- 
related changes like CIN. p16INK4a has recently been 
described as a surrogate marker for HR-HPV.
 Associated squamous and glandular 
intraepithelial lesions of the cervix. It has been also 
demonstrated that the immunohistochemical staining 
pattern of p16INK4a is different in high-grade 
intraepithelial neoplasia of the uterus (CIN2 and 3), 
where it diffuse, from sporadic or focal staining patterns 
in CIN1 [18, 19].
 p16INK4a immunostaining allow precise 
identification of even small C1N or cervical cancer 
lesions in biopsy sections and helped to reduce 
interobserver variation in the histopathologic 
interpretation of cervical biopsy specimens [22]. 
 Thus, p16 IHC can reduce false-negative 
and false-positive biopsy interpretation and thereby 
significantly improve cervical (pre)-cancer diagnosis, 
and also p16INK4a negative CIN1 may benefit from 
a less intensive follow-up as they rarely progress to 
high grade.
 One of the significant disadvantages of the 
current existing screening tests is their inability to 
discriminate between lesions that will progress and 
those that do not [20].
 To surmount the current tests limitations, a test 
is required that indicates that an oncogenic HPV virus 
has already enhanced genetic instability and rendered 
infected cells susceptible to transformation, that leads 
to the development of cancer, which is, a test for HR 
HPV that indicates the virus will exert its oncogenic 
potential in that particular woman [12]
 A number of studies have focused on the 
utility of p16INK4a immuno-staining as a marker of 
identifying dysplastic lesions caused by HR HPV and 
also in distinguishing non-HPV-related changes, such 
as squamous metaplasia, inflammatory conditions or 
reactive conditions that either mask or mimic dysplasia 
in cervical biopsy specimen; from HPV-related changes 
like CIN1 [21]. 
 p16INK4a has recently been described as a 
surrogate marker for HR-HPV associated squamous 
and glandular intraepithelial lesions of the cervix. It has 
been also demonstrated that the immunohistochemical 
staining pattern of p16INK4a is different in high-grade 
intraepithelial neoplasia of the cervix (CIN2 and 3), 
where it is diffuse, from sporadic or focal staining 
patterns in CIN1 [22]
 According to Klaes et al., there was a 
significantly better agreement in the interpretation 
of p16INK4a expression which was restricted to 
CIN2 / CIN3, CIN1 associated with high-risk Human 
Papillomavirus, or cervical cancer. p16INK4a 
immunostaining allowed precise identification of 
even small CIN or cervical cancer lesions in biopsy 
sections and helped to reduce interobserver variation 
in the histopathologic interpretation of cervical biopsy 
specimens [36]. 
 Thus, p16IHC can reduce false-negative 
and false-positive biopsy interpretation and thereby 
significantly improve cervical (pre)-cancer diagnosis 
and also p16INK4a negative CIN1may benefit from a 
less intensive following up as they rarely progress to 
high grade [19].
AIM
 To determine the role of p16INK4a in early 
diagnosis of cervical cancer from cervical lesions using 
cellblocks in patients referred for colposcopic biopsy
Methodology
Study Site
 The study was carried out at KNH ‘s reproductive 
health unit clinic (clinic 66). This clinic deals with 
specialized gynaecological related complications
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Study Design
 This was a laboratory-based, prospective study 
with a parallel comparative arm.
Data Collection Methodology
 Patients whose Pap smear reports had been 
recommended for colposcopy were recruited for the 
study. Those who consented had smear samples taken 
using a cytobrush. The cytobrush was put in a labelled 
centrifuge tube containing AA fixative and cocked 
ready for transportation to the laboratory. 
 They were then centrifuged, supernatant 
discarded and the brush discarded. 10ml of the fixative 
was added to each of the deposits centrifuged and the 
supernatant discarded. This procedure was repeated 2 
times. 10% formalin was added and left to stand for 4 
hrs. The deposits were picked using forceps wrapped 
in a filter paper and processed in a tissue processor, 
embedded and cellblocks prepared.
 The corresponding colposcopic biopsies 
were retrieved from Histopathology laboratory at 
Kenyatta National Hospital and both the cellblocks 
and Colposcopy biopsies were subjected to the routine 
histological tests (H & E) and the P16 biomarker tests. 
The results were interpreted by the PI together with the 
pathologist and results recorded.
Results
 Samples were collected from a study population 
(N) of 69 for analysis out of which a sample population 
(n) of 58 met the inclusion criteria. The sampling 
procedure which was based on the previous Pap smear 
test results were included in this study. The  Pap smear 
specimens had either HSIL, LSIL, ASCUS AGUS
 From Table 1: 58 of 69 cases analyzed 
Biomarker Colposcopy had (43%) 30 negativity and 
(41%) 28 positivity while Cellblock had negativity of 
(46%) 32 and positivity of (38 %) 26
Colposcopy had (39%) 27 negatives and (45%) 31 
positives while Cellblock had (48%) 33 negative and 




Lsil 11 CIN1 16
Hsil 9 CIN2 10
Ascus 5 CIN3 5
Total 25 TOTAL 31
Table 1: The Overall Distribution Of The Tests
 Negative Positive
Biomarker cellblock 32 26
Biomarker colposcopy 30 28
HE_cellblock 33 25
HE_colposcopy 27 31
Pap smear 26 32
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 Out of the 58 cases on the routine histological 
stain (Haematoxyline and Eosin) carried out, LSIL were 
11(18%) of all cases HSIL 9 (15%)  ASCUS 5 (8%) on 
The table for P values
Table 1: Biomarker Cellblock , Colposcopy and Pap Smear
 Biomarker Cellblock





Negative 21 9 30 0.018
Positive 11 17 28




Negative 18 8 26 0.046
Positive 14 18 32
Total 32 26 58
Cellblock and on Colposcopy CIN1 were 16 (28%) cases 
CIN2 10 (17%),   CIN3 5 (8%) 
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Table 2: HE_Cellblock Colposcopy & Pap smear          
 From Table 2: it was observed that there 
was significance in the Biomarker tests carried on 
the Cellblock and Colposcopic biopsies having a 
significance of  0.018 which is below 0.05 indicating a 
level of agreement and hence a cellblock could be used 
in place of colposcopic biopsy. 
 Similarly for the routine histological stain, there 
was significance in both the cell block and colposcopic 
biopsy , Cell block and Pap smear with P values of 0.047 
and 0.001 respectively indicating that cell block remains 
a useful screening and diagnostic tool for early cervical 
cancer detection. 
Table 3: Biomarker Cellblock   
Specificity and Sensitivity of The Tests   
Haematoxyline & Eosin Cellblock 





Negative 19 8 27 0.047
Positive 14 17 31




Negative 21 5 26 0.001
Positive 12 20 32
Total 33 25 58
 Biomarker Cellblock




Pap smear 72%  69.7%
Table 4: HE_Cellblock   
HE cellblock
Sensitivity        Specificity
HE Colposcopy 51.4% 65.2%
Pap smear 60% 66.7%
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Discussion, Conclusion & 
Recommendation
1.1  Discussion
p16 is a widely used surrogate marker for HPV related 
cervical dysplasia. It is believed to have a high diagnostic 
efficacy in the determination of a transient and chronic 
HPV infection.
 The study enrolled 69 participants whose 
samples were collected out of which 58 met the inclusion 
criteria, and 11 samples were inadequate to proceed for 
investigation. The age range of the participants was 21- 
70 years with a mean age of 43.2029 and the standard 
deviation of 9.771778.
Expression of p16INK4a on Cell Blocks & Colposcopy Biopsies
Colposcopy Tissue Biopsy Cell Block Preparations
 +p16INK4a Colposcopy Biopsy
-ve p16INK4a Colposcopy Biopsy
 +p16INK4a Cellblock Biopsy
-ve p16INK4a Cellblock Biopsy
+QC
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 There was a significant level of agreement 
between Pap smears and Cellblock findings on the 
routine histological stain. 
 Of the 58 cases analyzed, Colposcopy had (39%) 
27 negatives and (45%) 31 positives while Cellblock had 
(48%) 33 negative and (36%) 25 positive. 
 Biomarker Colposcopy had (43%) 30 negativity 
and (41%) 28 positivity while Cellblock had negativity of 
(46%) 32 and positivity of (38 %) 26.
 Pap smear compared to biomarker cellblock had 
a p-value of 0.046 showing a significance agreement and 
routine histology stain for Cellblock. 
 Pap smear had a p-value of 0.001. This indicated 
that a Cellblock can be useful for screening and diagnosis 
as there was a significant level of agreement between the 
two tests. 
  
 Hence, there will be a minimal loss to follow 
up and  avoid the need for highly specialized and 
significantly cut the cost of screening equipment 
currently in use for the gold standard.
 The difference in variation of Cellblock on 
H&E and Biomarker could be as a result of Cellblock 
preparations sampling techniques, processing of 
Colposcopic biopsies, degradation of the tissue block 
and the existing inter and intraobserver variability.
 The sensitivity of Colposcopy is at 88.88% as 
compared to the low sensitivity of Pap test estimated 
to be 44.44%, the primary reason why colposcopy is 
regarded as gold test/confirmatory test for cervical 
cancers [40]. 
 The sensitivity of Colposcopy is known to range 
from 87% to 99% as compared to the sensitivity of 
Cellblock ranges from 90% to 94.5%, but the sensitivity 
can be increased for cyto diagnosis at analytical stages.
 Cervical screening, p16 is still an excellent 
surrogate marker highly useful for detection of 
dysplastic lesions. The cell cycle regulator overexpressed 
in Squamous Dysplasia and Cellblock together with 
Colposcopy can be used to further diagnostic accuracy 
of dysplastic lesions.
 Mitigate inter and intra-observer variation, loss 
to a follow up, late presentation of patients, unnecessary 
invasive procedures and misdiagnosis results to mis-
management.
 The gold standard test for cervical malignancy, 
stained with H&E gives a false impression of a static 
process that lacks the ability to demonstrate the 
progression from pre-to malignancy. 
 On contrast cellblock with H&E and BM has 
the potential to distinguish CIN from other lesions and 
distinguish chronic from the transient.
 Cellblock if well prepared and well sampled 
could serve as a tool for screening, diagnosing and a 
confirmatory for pre and malignant cervical lesions as 
it provides multiple sections paving way for additional 
markers that may be used for further testing and 
diagnostic markers that would improve on patient's 
further management.
 
 The p16 expression has been shown to be 
associated with Neoplastic Nquamous and Glandular 
Intraepithelial lesions due to the complex molecular 
mechanisms, where high-risk HPV transforming 
proteins interact with cell cycle proteins to generate a 
futile feedback loop, resulting in p16 overexpression 
[39]. 
 Diffuse p16 expression in immunoperoxidase 
study can thus serve as a surrogate marker of transformed 
high-risk HPV-related cervical lesions and represent a 
significant means for the pathologist to separate lesions 
requiring colposcopy from those that do not [40]. 
 The single most common cause of an inadequate 
biopsy specimen is the failure to provide abnormal 
tissue of sufficient amount and depth[41]. 
 Without the underlying stroma, an invasive 
neoplasm is likely to be interpreted as an in situ lesion. 
On the prognostic significance of p16 especially in LSIL 
prediction of regression or progression to malignancy.
1.2   Conclusion
 The two histological testing techniques; 
Colposcopy and Cellblock, agree on the variables 
examined. The methods highly agree when Hematoxylin 
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& Eosin is used as a staining procedure for both 
colposcopy and cellblock. There was a considerable 
variation on the number of negative and positive results 
between the histological assessment using the Pap test as 
compared to both colposcopy and cellblock techniques. 
 For cervical cancer screening, p16INK4a is still 
an excellent surrogate marker useful for the detection of 
lesion likely to progress to malignancy. 
 The cell cycle regulator p16 INK4a is shown to 
be overexpressed in Squamous Dysplasia and cellblock 
together with colposcopy techniques can be used to 
improve further the diagnostic accuracy of ASC-H 
Papanicolaou smears and to reduce unnecessary 
procedures and over treatment cases.   
 From the study, it can be concluded that 
cellblock with Haematoxylin and Eosin staining and 
biomarkers p16INK4a is a singnificant tool for the 
confirmatory test of the cervical cytological specimen 
when examining pre-malignant lesions. 
 Also, the disparity arising from cellblock can 
be due to deviation from the standardized procedures of 
cutting surfaces towards achieving excellent cellularity. 
 
 Through the cellblock techniques, this study 
proves to be a confirmatory test for the diagnosis of 
ASC-H Pap tests. Multiple unstained slides producing 
adequate cellularity can be obtained from each cell block 
paving way for additional markers that can increase the 
diagnostic specificity and sensitivity to be used.
 From this study, Colposcopy Technique. Cell 
block techniques ties with the gold test of colposcopy 
for cervical screening with some areas to be improved 
on the cell block.
 Based on the study findings, sensitivity ranges 
for colposcopy and cell block methods for cyto-diagnosis 
is visible.  
 In consideration of other aspects such as 
affordability of the services, loss of follow-ups, 
equipment required and capacity building, it can be 
concluded that cell block seems to be a better choice for 
the Kenyan population. 
 With colposcopy, personnel needs to go through 
specialized training. Currently, the test is done by the 
obstetrician/ gynecologists as compared to Cellblock 
that can be done by a nurse or medical officer in the 
facility.  
 Although the sensitivity, specificity and 
diagnostic accuracy of cell block vary, through this study, 
is preferred as compared to colposcopy, Colposcopy is 
at crossroads due to issues with efficiency, cost and 
comfort consideration. 
 Most often, Colposcopy should not be 
recommended to be done as a random biopsy on patients 
with normal - appearing cervices. 
 This means, primary test such as Pap smear 
must be done first because Coloscopy makes it more 
unaffordable and inaccessible to many patients. The 
sensitivity of Colposcopy procedure can only be 
increased by taking two or more biopsies instead of one 
as the case of cell block where samples are obtained 
once.
References
1. D. M. Parkin, “Global cancer statistics in the year 
2000,” Lancet Oncology. 2001.
2. N. P. et al., “Efficacy of HPV DNA testing with 
cytology triage and/or repeat HPV DNA testing 
in primary cervical cancer screening,” J. Natl. 
Cancer Inst., 2009. 
3)    L. Pantanowitz, M. Hornish, and R. Goulart, 
“The impact of digital imaging in the field of 
cytopathology,” Cytojournal, 2009.
4. C. B. Visioli et al., “hr-HPV testing in the follow-
up of women with cytological abnormalities and 
negative colposcopy,” Br. J. Cancer, 2013.
5. M. Safaeian, D. Solomon, and P. E. Castle, 
“Cervical Cancer Prevention-Cervical Screening: 
Science in Evolution,” Obstetrics and Gynecology 
Clinics of North America. 2007.
6. P. Cristiani et al., “Rationale and development 
of an on-line quality assurance programme 
for colposcopy in a population-based cervical 
screening setting in Italy,” BMC Health Serv. Res., 
2013.
48 African Journal of Health Sciences, Volume 32, Issue No. 2, March - April 2019
7. J. Li, M. J. Poi, and M. D. Tsai, “Regulatory 
mechanisms of tumor suppressor p16INK4a and 
their relevance to cancer,” Biochemistry, 2011.
8. S. K. Ghosh et al., “Human papillomavirus 
testing for suspected cervical cancer patients from 
Southern Assam by fast-PCR.,” Asian Pac. J. 
Cancer Prev., 2011.
9. V. B. Shidham, R. Mehrotra, G. Varsegi, K. 
D’Amore, B. Hunt, and R. Narayan, “p16INK4a 
immunocytochemistry on cellblocks as an adjunct 
to cervical cytology: Potential reflex testing on 
specially prepared cellblocks from residual liquid-
based cytology specimens,” Cytojournal, 2011.
10. E. Burd, “Human papillomavirus and cervical 
cancer Burd E (2003) Human papillomavirus 
and cervical cancer. Clin. Microbiol Rev 16: 1–17 
Available at: http: // www.sciencedirect.com /
science / article / pii / S0140673607614160,” 
 Clin.  Microbiol Rev, 2003.
11. A. Castanon, R. Landy, and P. D. Sasieni, “Is 
cervical screening preventing adenocarcinoma 
and adenosquamous carcinoma of the cervix,” Int. 
J. Cancer, 2016.
12. J. L. Wang et al., “p16INK4a and laminin-
5γ2 chain expression during the progression of 
cervical neoplasia,” Acta Oncol. (Madr)., 2006.
13. U. K.-E. et al., “Prediction of spontaneous 
regression of cervical intraepithelial neoplasia 
lesions grades 2 and 3 by proteomic analysis,” Int. 
J. Proteomics, 2014.
14. S. Shrivastava, D. Barmon, P. Deka, and A. 
Kataki, “Vaginal vault carcinoma as second 
primary in a treated case of ovarian cancer,” J. 
Midlife. Health, 2012.
15. S. Nishio et al., “p16INK4a immunohisto-
chemistry is a promising biomarker to predict 
the outcome of low grade cervical intraepithelial 
neoplasia: Comparison study with HPV 
genotyping,” J. Gynecol. Oncol., 2013.
16. R. Klaes et al., “p16INK4a immuno-
histochemistry improves inter-observer agreement 
in the diagnosis of cervical intraepithelial 
neoplasia,” Am. J. Surg. Pathol., 2002.
17. H. G. Kaspar and C. P. Crum, “The utility 
of immunohistochemistry in the differential 
diagnosis of gynecologic disorders,” Arch. Pathol. 
Lab. Med., 2015.
18. D. Q. Liu et al., “Increased RIPK4 expression is 
associated with progression and poor prognosis in 
cervical squamous cell carcinoma patients,” Sci. 
Rep., 2015.
19. F. S. Aslani, A. Safaei, M. Pourjabali, and M. 
Momtahan, “Evaluation of Ki67, p16 and CK17 
markers in differentiating cervical intraepithelial 
Neoplasia and benign lesions,” Iranian Journal of 
Medical Sciences. 2013.
20. E. R. Nijhuis et al., “An overview of innovative 
techniques to improve cervical cancer screening,” 
Anal. Cell. Pathol., 2006.
21. I. Rufforny, E. J. Wilkinson, R. Redman, N. 
A. Massoll, and C. Liu, “p16ink4a Is Helpful in 
Discriminating Between Cervical Intraepithelial 
Neoplasia 1 and Equivocal Lesions of the Cervix,” 
J. Low. Genit. Tract Dis., 2006.
22. I. Tsoumpou et al., “p16INK4 aimmuno-
staining in cytological and histological 
specimens from the uterine cervix: A systematic 
review and meta-analysis,” Cancer Treatment 
Reviews. 2009.
